SCIREQ to offer tremoFlo for preclinical research

Just in time for the upcoming ATS meeting in Denver, Colorado, we are excited to announce a worldwide exclusive distribution partnership with SCIREQ Scientific Respiratory Equipment Inc. to make the tremoFlo available for preclinical research.

SCIREQ possesses an in-depth knowledge of the needs and applications of scientists engaged in preclinical pulmonary research. Along with its parent company, emka Technologies, SCIREQ has access to an extensive worldwide distribution, service and support network that allows them to reach and provide outstanding service to researchers around the globe.

Unique Solutions for Translational Research

Together, SCIREQ and THORASYS can offer a unique solution permitting a new level of quantitative lung function assessment in late-stage preclinical research, including Safety Pharmacology. The specially adapted tremoFlo P-100 closes the gap between the clinically oriented tremoFlo C-100  and SCIREQ’s flexiVent system, now providing a continuous and coherent suite of products for translational pulmonary research from bench to bedside.

For further information, refer to the SCIREQ news release here. To enquire about the tremoFlo P-100, please contact SCIREQ via www.scireq.com.

The tremoFlo™ C-100 Airwave Oscillometry System (AOS) Final nominee at the 2015 Manning awards

Thorasys is proud to announce that Dr. Geoff Maksym of Dalhousie University and Dr. Thomas Schuessler President of Thorasys are the final 2015 Manning Innovation Award nominees for their innovative tremoFlo™ C-100 Airwave Oscillometry System (AOS) ™.

The 34th Manning Awards will be held on October 2nd 2015 in Saskatoon, SK.

https://twitter.com/ManningAwardsCA/status/581187021798043648

Welcome to ERS 2014!

Today was the first day of the exhibit at 2014 ERS Congress in Munich, Germany, and we were happy to welcome many visitors at our booth. For more opportunities to meet our team, get a live demonstration of the tremoFlo and discuss lung function assessment without patient effort, stop by Hall A1 Booth D.15 near the ERS Lounge during the following times:

  • Monday September 8th, 9:00am-5:00pm
  • Tuesday September 9th, 9:00am-5:00pm
  • Wednesday September 10th, 9:00am-12:00pm

We look forward to seeing you in Munich!

ERS2014Thorasys

tremoFlo™ Airwave Oscillometry System at ERS 2014

Join us at ERS 2014 in Munich, Germany from September 7th-10th! We invite you to visit us in the exhibit hall in Hall A1 at Booth D.15 for a demonstration of the tremoFlo™ C-100 Airwave Oscillometry System (AOS™). The exhibit will be open as follows:

 

  • Sunday, September 7th, 9 am to 5 pm
  • Monday, September 8th, 9 am to 5 pm
  • Tuesday, September 9th, 9 am to 5 pm
  • Wednesday, September 10th, 9 am to 12 pm

 

We look forward to seeing you!

 

Your THORASYS Team

 

tremoFlo™ featured on Channel 7 News

Channel 7 News featured the tremoFlo™ Airwave Oscillometry System being used to help assess childhood asthma in Sydney, Australia.

The original news report is available on the Channel 7 News website at http://au.news.yahoo.com/video/watch/24390699/asthma-breakthrough/.

This report was inspired by a recent study from researchers at the Woolcock Institute looking at the day-to-day variability of childhood asthma entitled “Increased Day-To-Day Variability of Forced Oscillatory Resistance in Poorly Controlled or Persistent Paediatric Asthma“.

Newly TGA-certified tremoFlo™ C-100 on display at TSANZSRS

The tremoFlo Airwave Oscillometry System continues to break ground in markets around the world. Only a few weeks after approval in Europe and Canada, we have earned approval by the Australian Therapeutic Goods Administration (TGA), so that the tremoFlo is now available for diagnostic and clinical use in Australia.

“I very much want to thank our team for their great work and enthusiasm as they continue to execute our regulatory strategy on or even ahead of schedule” says Dr. Thomas Schuessler, President and CEO of THORASYS. “Australia is known to excel in pulmonary research and medicine, and we are happy to serve this knowledgeable customer base.”

TSANZSRS Hero

The tremoFlo Airwave Oscillometry System will be on display at the joint Thoracic Society of Australia and New Zealand and Australia and New Zealands Society for Respiratory Science (TSANZRS) conference on April 4-9 in Adelaide. Come visit us at the BIRD Healthcare booth within the exhibition hall. We hope to see you there!

[ email hidden; JavaScript is required | View TGA Certificate | Follow us on TwitterConnect on LinkedIn ]

tremoFlo™ C-100 is now Health Canada approved!

The entire THORASYS team is happy to announce we have obtained our Health Canada certificate for the tremoFlo C-100. This is a proud moment for any Canadian medical device company, and we are excited to begin sales in Canada. Hospitals, clinics and research facilities across Canada can now offer effortless lung function measures to patients of all ages, including children as young as two years old.

tremoFlo Snow

Heidi Giesbrecht, Product Manager, said “to be certified in your home market is a great achievement. We look forward to working with all of our current and new customers in Canada. Next we will turn our attention to certification with the FDA in the coming months.”

[ email hidden; JavaScript is required | View Health Canada Certificate | Follow us on TwitterConnect on LinkedIn ]

tremoFlo™ C-100 Airwave Oscillation System™ receives CE Mark

We are pleased to announce that on January 8, 2014, our tremoFlo C-100 Airwave Oscillometry System received its CE Mark as a class II medical device. This makes the tremoFlo C-100 the first and only approved handheld Oscillometry system for effortless lung function testing in Europe.

tremoFlo CE Mark small

“The CE Mark is an important milestone on our regulatory and go-to-market roadmap,” says Thomas F. Schuessler, President and CEO of THORASYS Thoracic Medical Systems Inc. “I would like to thank all members of our excellent team for their dedication and hard work that has allowed us to reach this important milestone on schedule.”

Europe is the first jurisdiction where the tremoFlo C-100 is authorized as a medical device to diagnose and monitor lung disease. Applications for regulatory approval are currently in progress in a variety of other jurisdictions, including Canada and the United States, and updates will be provided regularly on this blog.

[email hidden; JavaScript is required | View CE Certificate | Follow on Twitter | Connect on LinkedIn]

Thorasys is awarded ISO 13485 certification

THORASYS Thoracic Medical Systems Inc. is proud to announce that on December 2nd, 2013 we obtained our ISO 13485:2003 certificate by the British Standards Institute (BSI).


This is an important milestone for THORASYS as ISO 13485 is a major certification required for medical devices.
A requirement for certification is a thorough verification and assessment of the organisation’s Quality Management System and design and manufacturing installations by a neutral accredited auditor.


“Receiving the ISO 13485 certification is an acknowledgement of our ongoing commitment to the highest quality throughout Thorasys operations. The certification is a requirement to register the tremoFlo™ C-100 in many regions and we are excited moving forward. We anticipate commercialization of the tremoFlo in Europe and Canada within the coming weeks,” said Sébastien Jutras, VP Operations.


The certificate can be viewed here.
If you have any questions about the certification standard, please contact THORASYS at email hidden; JavaScript is required.
Follow us on Twitter @Thorasys
Connect with THORASYS on LinkedIn